Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

CRDF

Live52w low +12.8%

Annual Quarterly

Core line items from CRDF's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: CARDIFF ONCOLOGY, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-07-27	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$71.40K	$41.00K	$593.00K	$350.00K	$230.00K
Operating Income	Not available	$-12.85M	$-48.96M	$-41.13M	$-29.16M
Net Income	Not available	$-12.35M	$-45.85M	$-38.63M	$-13.94M
EPS (Diluted)	$-0.14	$-0.18	$-0.69	$-0.58	$-0.41
Total Assets	Not available	$49.17M	$61.88M	$63.78M	$75.74M
Total Liabilities	Not available	$14.46M	$16.50M	$14.99M	$17.13M
Cash & Equivalents	Not available	$8.54M	$17.47M	$10.13M	$10.78M
Free Cash Flow OCF − CapEx	Not available	Not available	$-37.97M	$-32.00M	$-21.15M
Shares Outstanding	Not available	68.37M	68.31M	67.09M	66.53M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from CRDF's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +12.8%

Entity: CARDIFF ONCOLOGY, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-07-27	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$71.40K	$41.00K	$593.00K	$350.00K	$230.00K
Operating Income	Not available	$-12.85M	$-48.96M	$-41.13M	$-29.16M
Net Income	Not available	$-12.35M	$-45.85M	$-38.63M	$-13.94M
EPS (Diluted)	$-0.14	$-0.18	$-0.69	$-0.58	$-0.41
Total Assets	Not available	$49.17M	$61.88M	$63.78M	$75.74M
Total Liabilities	Not available	$14.46M	$16.50M	$14.99M	$17.13M
Cash & Equivalents	Not available	$8.54M	$17.47M	$10.13M	$10.78M
Free Cash Flow OCF − CapEx	Not available	Not available	$-37.97M	$-32.00M	$-21.15M
Shares Outstanding	Not available	68.37M	68.31M	67.09M	66.53M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.